Last reviewed · How we verify
NCT04318600
Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis
Completed
Phase 1
Last updated 24 March 2020
What this trial tests
Phase 1 trial testing human amniotic mesenchymal stem cell in Lupus Nephritis in 16 participants. Completed in 1 January 2019.
Timeline
1 January 2014
Primary endpoint
1 March 2017
1 March 2017
1 January 2019
Quick facts
| Lead sponsor | Yan'an Affiliated Hospital of Kunming Medical University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 1 January 2014 |
| Primary completion | 1 March 2017 |
| Estimated completion | 1 January 2019 |
Drugs / interventions tested
- human amniotic mesenchymal stem cell — full drug profile →
Conditions studied
- Lupus Nephritis — all drugs for Lupus Nephritis →
- Mesenchymal Stem Cells — all drugs for Mesenchymal Stem Cells →
Sponsor
Yan'an Affiliated Hospital of Kunming Medical University
Who can join
Adults 14 to 60, any sex, with Lupus Nephritis or Mesenchymal Stem Cells. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study would further evaluate the safety and efficacy of human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis (LN).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.
Dai X, Fan Y, Zhao X. · · 2025 · cited 78× · PMID 40097390 · DOI 10.1038/s41392-025-02168-0 -
Characteristics and Therapeutic Potential of Human Amnion-Derived Stem Cells.
Liu QW, Huang QM, Wu HY, Zuo GS, et al · · 2021 · cited 77× · PMID 33478081 · DOI 10.3390/ijms22020970 -
MSCs vs. iPSCs: Potential in therapeutic applications.
Thanaskody K, Jusop AS, Tye GJ, Wan Kamarul Zaman WS, et al · · 2022 · cited 59× · PMID 36407112 · DOI 10.3389/fcell.2022.1005926 -
Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges.
Chen F, Chen N, Xia C, Wang H, et al · · 2023 · cited 30× · PMID 37013255 · DOI 10.1177/09636897231164251 -
Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors?
El-Jawhari JJ, El-Sherbiny Y, McGonagle D, Jones E. · · 2021 · cited 30× · PMID 33732263 · DOI 10.3389/fimmu.2021.643170 -
When Origin Matters: Properties of Mesenchymal Stromal Cells From Different Sources for Clinical Translation in Kidney Disease.
Calcat-I-Cervera S, Sanz-Nogués C, O'Brien T. · · 2021 · cited 24× · PMID 34616756 · DOI 10.3389/fmed.2021.728496 -
The therapeutic effect of mesenchymal stem cells in diabetic kidney disease.
Habiba UE, Khan N, Greene DL, Shamim S, et al · · 2024 · cited 19× · PMID 38418620 · DOI 10.1007/s00109-024-02432-w -
A comparison of isolation and culture protocols for human amniotic mesenchymal stem cells.
Naeem A, Gupta N, Naeem U, Khan MJ, et al · · 2022 · cited 17× · PMID 35412950 · DOI 10.1080/15384101.2022.2060641
Verify or expand the search:
- PubMed search for NCT04318600
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lupus Nephritis
Currently open trials in the same condition.
- NCT07523542 — SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus · Phase 1, PHASE2 · recruiting
- NCT07109986 — UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis · Phase 1 · recruiting
- NCT07053891 — LUPKYNIS Drug-use Results Survey · recruiting
- NCT07015983 — A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I · Phase 2 · recruiting
- NCT06711887 — Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants · Phase 3 · recruiting
Other Yan'an Affiliated Hospital of Kunming Medical University trials
Trials by the same sponsor.
- NCT07469371 — CLEAR-AS: CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis · NA · recruiting
- NCT07485816 — A Study on the Correlation Between Cardiac-Cerebral Oxygenation Reserve and Cognitive Function Changes in Heart Failure · enrolling by invitation
- NCT06892730 — Safety and Efficacy of TEVAR Combined With Long Bare-metal Stents in the Intervention of ATBAD · NA · not yet recruiting
- NCT05611190 — CT-FFR-guided Strategy for In-stent Restenosis · NA · unknown
- NCT04125329 — Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04318600 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yan'an Affiliated Hospital of Kunming Medical University
- Last refreshed: 24 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04318600.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing